Source: European Journal of Pharmaceutics and Biopharmaceutics. Unidades: FMRP, SVOI, FCFRP
Subjects: ANTICORPOS MONOCLONAIS, NEOPLASIAS MAMÁRIAS, LIPOSSOMOS, ANTINEOPLÁSICOS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
ELOY, Josimar O. et al. Anti-HER2 immunoliposomes for co-delivery of paclitaxel and rapamycin for breast cancer therapy. European Journal of Pharmaceutics and Biopharmaceutics, v. 115, p. 159-167, 2017Tradução . . Disponível em: https://doi.org/10.1016/j.ejpb.2017.02.020. Acesso em: 11 nov. 2024.APA
Eloy, J. O., Petrilli, R., Chesca, D. L., Saggioro, F. P., Lee, R. J., & Marchetti, J. M. (2017). Anti-HER2 immunoliposomes for co-delivery of paclitaxel and rapamycin for breast cancer therapy. European Journal of Pharmaceutics and Biopharmaceutics, 115, 159-167. doi:10.1016/j.ejpb.2017.02.020NLM
Eloy JO, Petrilli R, Chesca DL, Saggioro FP, Lee RJ, Marchetti JM. Anti-HER2 immunoliposomes for co-delivery of paclitaxel and rapamycin for breast cancer therapy [Internet]. European Journal of Pharmaceutics and Biopharmaceutics. 2017 ; 115 159-167.[citado 2024 nov. 11 ] Available from: https://doi.org/10.1016/j.ejpb.2017.02.020Vancouver
Eloy JO, Petrilli R, Chesca DL, Saggioro FP, Lee RJ, Marchetti JM. Anti-HER2 immunoliposomes for co-delivery of paclitaxel and rapamycin for breast cancer therapy [Internet]. European Journal of Pharmaceutics and Biopharmaceutics. 2017 ; 115 159-167.[citado 2024 nov. 11 ] Available from: https://doi.org/10.1016/j.ejpb.2017.02.020
